UNSPSC 51287001: Acedapsone

This classification denotes a sulfone anti-infective agent with the molecular formula C16H16N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0GZ72U84TN, chemically known as 4,4-sulphonyldianiline but more generally known as acedapsone, which bears US NIH Compound Identifier 2955. European Medicines Agency schedules Acedapsone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05201MIG.

The term ACEDAPSONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 24, No. 11 1970, List 10). ACEDAPSONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(C1CCC(N)CC1)C1CCC(N)CC1.

UNSPSC 51287001 Acedapsone, a Commodity code, does not reflect the actual work state and local governments are procuring under this taxonomy entry. Recent opportunities tagged with this code involve naloxone distribution, direct-to-manufacturer pharmaceutical programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceutical distribution through cooperative purchasing — none of which align with acedapsone, a specialized antimicrobial agent. The code shows a mismatch between its nominal pharmaceutical classification and the health-system procurement activity it purports to capture, suggesting either miscoding in the issuing systems or a fundamental disconnect between the UNSPSC taxonomy and the purchasing bodies' classification practices.

The four recent opportunities posted between January and June 2026 span state health agencies, county health departments, city fire services, and multistate cooperative purchasing alliances. Seminole County, Florida is procuring naloxone and drug deactivation systems through an IFB due July 26, 2023 (note: the posted date of June 30, 2026 conflicts with the due date, indicating a data quality issue in the source). The Texas Health and Human Services Commission issued a Request for Information in March 2026 to explore direct-to-manufacturer pharmacy programs. The City of Tampa solicited medical and first aid supplies for its Fire Department Rescue Division via IFB (26P00145, due March 13, 2026, estimated $700,000, designated for certified Small Local Business Enterprises with a 5% bid discount). Minnesota's multistate cooperative purchasing alliance (MMCAP) issued an RFP due March 26, 2026 for generic pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local facilities in Minnesota and Oregon. Given the mismatch between code and activity, this code should be flagged for reclassification review rather than pursued as a reliable indicator of actual state and local pharmaceutical procurement.